dc.contributor.author | Marchbank, T | |
dc.contributor.author | Limdi, JK | |
dc.contributor.author | Mahmood, A | |
dc.contributor.author | Elia, G | |
dc.contributor.author | Playford, RJ | |
dc.date.accessioned | 2010-05-25T14:49:59Z | |
dc.date.available | 15-09-2008 | |
dc.date.available | 2010-05-25T14:49:59Z | |
dc.date.issued | 2010-05-25T14:49:59Z | |
dc.identifier.issn | 0269-2813 | |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/164 | |
dc.description.abstract | Background A partially hydrolysed and dried product of pacific whiting fish is marketed as a health food supplement supporting 'intestinal health'.Aim To examine whether the partially hydrolysed and dried product of pacific whiting fish influenced the small intestinal damaging side effects of the nonsteroidal anti-inflammatory drug, indomethacin.Methods Eight human volunteers completed a double-blind, placebo-controlled, crossover protocol of clinically relevant dose of indomethacin (50 mg t.d.s. p.o. for 5 days) with 7 days of fish hydrolysate or placebo starting 2 days prior to indomethacin. Changes in gut permeability were assessed using 5 h urinary lactulose:rhamnose (L/R) ratios.Results Fish hydrolysate given alone did not affect permeability. In the main study (n = 8), baseline values were similar for both arms (0.28 +/- 0.05 and 0.35 +/- 0.07). Administration of indomethacin (+placebo) caused a fivefold rise in L/R ratios (increasing to 1.54 +/- 0.35), whereas L/R ratios in the same subjects ingesting indomethacin + fish hydrolysate was only 0.59 +/- 0.14 (P < 0.01 vs. indomethacin alone). Dyspeptic symptoms occurred in four of eight subjects taking indomethacin alone, but zero of eight when hydrolysate was co-administered.Conclusion Natural bioactive products (nutriceuticals), such as fish hydrolysates, may provide a novel approach to the prevention and treatment of NSAID-induced and other gastrointestinal injurious conditions. | |
dc.format.extent | 799 - 804 | |
dc.language | EN | |
dc.publisher | BLACKWELL PUBLISHING | |
dc.relation.isreplacedby | 123456789/178 | |
dc.relation.isreplacedby | https://qmro.qmul.ac.uk/jspui/handle/123456789/164 | |
dc.subject | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | |
dc.subject | HEALTH FOOD SUPPLEMENT | |
dc.subject | PERMEABILITY | |
dc.subject | DAMAGE | |
dc.subject | GUT | |
dc.subject | N-3 | |
dc.title | Clinical trial: protective effect of a commercial fish protein hydrolysate against indomethacin (NSAID)-induced small intestinal injury | |
dc.identifier.doi | 10.1111/j.1365-2036.2008.03783.x | |
pubs.issue | 6 | |
pubs.volume | 28 | |